Inconsistent dosing can affect appetite regulation and delay progress
Review on Contaminants in Edible Oil and Analytical Technologies. Oil Crop Science, vol
The new Phase 3 efficacy numbers According to Lillys May 21, 2026 release, the primary endpoint at 80 weeks showed the following mean body-weight changes: 4 mg: -19.0% ( -47.2 lbs ) 9 mg: -25.9% ( -64.4 lbs ) 12 mg: -28.3% ( -70.3 lbs ) placebo: -2.2% ( -5.5 lbs ) 1 That is already enough to make the trial one of the most important obesity readouts of the year
Patients should seek medical evaluation for severe pain after injury, inability to bear weight, major swelling, deformity, numbness, weakness, fever, signs of infection, worsening abdominal pain, blood in stool, persistent vomiting, chest pain, shortness of breath, or neurological symptoms